Dr Karin Bornfeldt
Disclosure details
Dr Bornfeldt has received research support from Novo Nordisk A/S and has published articles in collaboration with Ionis Pharmaceuticals.Edwin L. Bierman Professor of Medicine
Division of Metabolism, Endocrinology and Nutrition
Professor of Laboratory Medicine and Pathology
Director, Diabetes Complications Program, UW Medicine Diabetes Institute
Deputy Director, Diabetes Research Center
University of Washington
Karin Bornfeldt’s research is devoted to cardiovascular complications associated with diabetes. Her group uses a combination of human studies and research on mechanistic mouse models. Dr Bornfeldt’s current work is focused on apolipoprotein C3 and remnants of triglyceride-rich lipoproteins in cardiovascular risk associated with diabetes.
She received her PhD in Sweden in 1991, working with an academic endocrinologist, and then did a postdoctoral fellowship at the University of Washington in the laboratory of Dr. Russell Ross. She is now Edwin L. Bierman Professor of Medicine, Division of Metabolism, Endocrinology and Nutrition, and Professor of Laboratory Medicine and Pathology there. She serves as Director of the Diabetes Complications Program at the UW Medicine Diabetes Institute, as Deputy Director of the Diabetes Research Center, and as Director of a T32 Training Grant on obesity, nutrition and atherosclerosis.
Dr Bornfeldt is a Fellow of the American Heart Association (AHA), Associate Editor of Circulation Research, Guest Editor of Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB), and Associate Editor of the Journal of Lipid Research. Other honors include the AHA Russell Ross Memorial Lectureship in Vascular Biology (2013), the Edwin L. Bierman Lectureship, American Diabetes Association (2014), the Journal of Lipid Research Lectureship (2019), the ATVB Special Recognition Award in Vascular Biology (2020), the David Rubenstein Lectureship award (2020) and the George Lyman Duff Memorial Lectureship Award, AHA (2021).
